Meet with SandboxAQ at BIO
At SandboxAQ, we’re redefining the future of drug discovery. Our physics-based AI platform, AQBioSim, accelerates the development of small molecules and biologics by delivering faster, more precise solutions to some of the toughest challenges in early R&D — from target identification through lead optimization and clinical candidate nomination.
We’ll be attending BIO International 2025 and would welcome the opportunity to connect and discuss how AQBioSim can help accelerate your discovery pipeline.
Andrea Bortolato, Ph.D., VP of Drug Discovery
Andrea brings over 20 years of experience in computational chemistry and drug discovery. He has held leadership roles at BMS, Schrödinger, Heptares (now Nxera Pharma), and Syngenta, and collaborated with industry leaders such as Takeda, AstraZeneca, Cubist, Morphic, and Structure Therapeutics. Andrea has authored over 50 patents and publications, including three in Nature. He earned his Ph.D. from the University of Padua and the University of Geneva, and completed his postdoctoral research at Mount Sinai in New York.
Betty Wong, Ph.D., Business Development Lead
Betty leads business development for SandboxAQ’s BioSim platform, working with pharma and biotech partners to deploy AQBioSim in oncology, immunology, and beyond. She has held strategy and partnership roles across the biotech, diagnostics, and life sciences industries, including at Adaptive Biotechnologies, DELFI Diagnostics, and Perkins Coie. Betty holds a Ph.D. in Biochemistry and Molecular Biophysics and an M.S. in Electrical Engineering from Caltech.